Are there clinical trials or published studies evaluating gelatide efficacy and safety?
Executive summary
There are no search results in the provided corpus that mention a product or molecule called “gelatide” or clinical trials specifically evaluating “gelatide” efficacy and safety; available sources discuss gelatin-based materials, gelatin as a plasma expander, and gel-based delivery platforms but do not mention “gelatide” (available sources do not mention gelatide). The literature provided highlights preclinical and early clinical activity for gelatin materials and GLP‑1 therapies but no named clinical trials or published human studies of “gelatide” [1] [2] [3].
1. No direct evidence for “gelatide” in supplied reporting
A targeted read of the supplied search results finds no article, trial registry entry, press release or review that names “gelatide” or reports trials of a molecule by that name; the sources instead cover topics such as gelatin-based drug‑delivery systems, gelatin used as a plasma expander, and firms’ gel platforms — but none identify or evaluate “gelatide” in humans or animals (available sources do not mention gelatide; [1]; [4]1).
2. What the sources do document: gelatin-based delivery research and preclinical findings
Multiple reviews and research articles in the provided set describe gelatin (GelMA, gelatin nanoparticles, gelatin‑based hydrogels) as a versatile biomaterial for drug delivery, tissue engineering and preclinical efficacy models — for example, GelMA composites for cartilage repair and gelatin nanoparticles for antibiotic delivery in osteomyelitis models — but these are predominantly preclinical or materials-science studies, not trials of a therapeutic agent named “gelatide” [4] [5] [1] [6].
3. Clinical studies focusing on gelatin as an excipient or embolic—not a new drug called “gelatide”
Where clinical data exist in the supplied sources, they relate to gelatin’s use in device/embolization contexts or to gelatin-containing formulations; reviews note clinical studies comparing embolic microspheres (including trisacryl gelatin microspheres) and document that clinical trials of empty gelatin-based delivery systems exist, but these compare delivery devices or excipients, not a drug entity called “gelatide” [1].
4. Safety signals and unresolved evidence gaps for gelatin in clinical use
Systematic reviews in the set raise safety and evidence concerns when gelatin is used systemically as a plasma expander: meta-analyses reported mixed signals on mortality, renal injury and particularly anaphylaxis risk, and concluded that safety and efficacy cannot be reliably assessed in some clinical settings because of limited or inconsistent trial data [7] [8]. Those findings apply to gelatin products used as volume expanders and point to existing clinical uncertainty around certain gelatin applications [7] [8].
5. Commercial and preclinical gel platforms are active — but not “gelatide” trials
Press materials and company releases included in the set describe proprietary gel delivery platforms and preclinical absorption improvements (e.g., Gelteq preclinical work showing increased early bioavailability in animal studies), which indicate commercial momentum for gel‑based delivery systems; none of these items report human randomized trials of a product named “gelatide” [3].
6. How to interpret the absence of “gelatide” in these sources
There are three straightforward possibilities consistent with the supplied corpus: (a) “gelatide” is an unpublished or internal code name not yet disclosed in public materials (available sources do not mention gelatide); (b) “gelatide” is a misremembered or misspelled name for an existing gelatin‑based product or platform (available sources do not mention gelatide); or (c) no clinical development of a product by that name has been publicly reported in the documents provided (available sources do not mention gelatide). The current sources cannot distinguish among those possibilities (available sources do not mention gelatide).
7. Practical next steps and evidence checkpoints
If you need a definitive answer for regulatory or clinical decisions, search ClinicalTrials.gov and major journal databases (PubMed, Nature Medicine collection pages shown in the corpus) for exact and variant spellings, sponsor names, and related trade or code names; the supplied results include ClinicalTrials.gov references and several trial-readout roundups that imply trial activity in adjacent fields [9] [10] [11]. If you share where you first heard “gelatide” (press release, label, social post, sponsor), I will re-check the provided documents for that context; current reporting in the supplied set does not document any clinical trials or published human studies of a molecule or product named “gelatide” (available sources do not mention gelatide).